By analyzing two large independent datasets, we show that PRMT5 overexpression is also associated with an increased risk of metastasis and adverse outcomes in patients with STS, suggesting important roles in sarcoma tumorigenesis and a potential role as a therapeutic target. The gene discussed is PRMT5; the disease is sarcoma.